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SUMMARY
Dedifferentiated chondrosarcoma is defined as a high-grade, anaplastic sarcoma adjacent to a low-grade malignant cartilage-forming
tumour. Controversy remains as to whether the anaplastic and cartilaginous components are derived from a common precursor cell, or
whether they represent separate genotypic lineages (collision tumour). Both components of a case of dedifferentiated chondrosarcoma
were therefore separately investigated by loss of heterozygosity (LOH) analysis, comparative genomic hybridization (CGH), DNA flow
cytometry, and p53 analysis. Both showed p53 overexpression and an identical somatic 6 bp deletion in exon 7 of p53. Combination of
the CGH and LOH results revealed that both components had lost the same copy of chromosome 13. These results provide compelling
evidence in this case for a common origin, instead of the ‘collision tumour’ theory. Certain genotypic alterations were not shared. The
anaplastic component showed severe aneuploidy, LOH at additional loci, and amplification and deletion of several chromosome parts.
In contrast, the cartilaginous component had lost chromosomes 5, 22, 17p and part of 16p and revealed an amplification of 17q. The
LOH and CGH results further demonstrated that the two components had lost a different copy of chromosome 4. Thus, a substantial
number of genetic alterations have occurred after the diversion of the two components, indicating that the separation of the two clones,
derived from a single precursor, was a relatively early event in the histogenesis of this case of dedifferentiated chondrosarcoma.
Copyright  1999 John Wiley & Sons, Ltd.
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The term dedifferentiated chondrosarcoma is applied
to a high-grade sarcoma occurring next to a low-grade
malignant cartilage-forming tumour; it comprises
approximately 10 per cent of all chondrosarcomas.1 The
tumour generally occurs after the age of 50 years, with
males and females equally affected.2 It is most often
located in the bones of the pelvis, the proximal femur or
humerus, the distal femur, and the ribs. Regardless of
treatment, the prognosis is ominous with 90 per cent of
patients dying with distant metastases within 2 years.3
Microscopically, the junction between the cartilagi-
nous and the non-cartilaginous anaplastic component is
remarkably sharp. The non-cartilaginous component
may express features of a malignant fibrous histio-
cytoma (MFH), osteosarcoma, fibrosarcoma, rhab-
domyosarcoma or angiosarcoma, with MFH features
most frequently present. In 25 per cent of cases, theCCC 0022–3417/99/130454–09$17.50
Copyright  1999 John Wiley & Sons, Ltd.diagnosis is made at the time of local recurrence.2
Distant metastases usually consist solely of the high-
grade anaplastic component.
Controversy remains as to whether the anaplastic and
cartilaginous components are derived from a common
precursor cell,4 or whether the anaplastic component
represents a separate genotypic lineage (collision
tumour).5–7 We investigated both components of a
case of dedifferentiated chondrosarcoma by loss of
heterozygosity (LOH) analysis, comparative genomic
hybridization (CGH), DNA flow cytometry, p53 immu-
nohistochemistry, and p53 mutation analysis, in order
further to elucidate the histogenesis of this rare entity.
MATERIALS AND METHODS
Clinical information
A 50-year-old female presented with a 6-month his-
tory of right sided hip complaints. Radiographs and CT
scan revealed a large lytic lesion in the diaphysis of the
proximal right femur, with intralesional calcifications
and cortical thickening. MRI revealed intermediate
signal intensity on the T1-weighted MR images and a
high signal intensity on the T2-weighted MR images.*Correspondence to: Judith V. M. G. Bovée, MD, Department of
Pathology, Leiden University Medical Centre, PO Box 9600, L1-Q,
2300 RC Leiden, The Netherlands. E-mail: JBovee@Pat.azl.nl
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455HISTOGENESIS OF DEDIFFERENTIATED CHONDROSARCOMACombined imaging features were therefore highly sug-
gestive of a malignant cartilaginous tumour. A Jamshidi
trocar biopsy was performed and histological examina-
tion revealed a chondrosarcoma grade II, according to
Evans.8 Subsequent treatment consisted of resection of
the tumour with reconstruction by inlay allograft. The
resected specimen showed at cut surface a grey white
glassy tumour within the proximal femur, with a length
of 8·5 cm. Routine sections demonstrated a moderately
cellular chondroid tumour with binucleated cells and
sporadic mitosis (grade II), next to a relatively small
high-grade undifferentiated component in the proximal
part of the resected specimen, reaching to the proximal
osteotomy. This component showed a spindle cell phe-
notype and a high number of mitoses (up to 3 per HPF),
in which focal transformation towards an osteosarcoma-
tous phenotype was seen, with focal deposition of
osteoid matrix surrounding the tumour cells. There was
an abrupt margin between the cartilaginous and ana-
plastic areas (Fig. 1). The case was additionally evalu-
ated by The Netherlands Committee on Bone Tumours
and the diagnosis of dedifferentiated chondrosarcoma
was supported after expert clinical-radiological and
pathological review. Staging studies revealed no evi-
dence of metastatic disease and adjuvant chemotherapy
(adriamycin and cisplatin) was administered.
Six months later, the patient re-entered the
clinic because of pain caused by tumour recurrence and
a disarticulation of the right leg was performed. Histo-
logical examination revealed highly cellular undifferen-
tiated tumour tissue with round-oval nuclei and
scattered mitoses. CT scan demonstrated multiple lung
metastases and the patient died 15 months after the first
diagnosis.
Specimens
From the cartilaginous component, formalin-fixed,
paraffin-embedded, and fresh frozen tumour tissue was
obtained from the proximal femur resection. From theCopyright  1999 John Wiley & Sons, Ltd.anaplastic component, formalin-fixed material was
available. Fresh frozen tissue from this component was
additionally derived from the amputation specimen.
DNA isolation
DNA isolation from fresh frozen tissue, with tumour
percentages estimated on cryostat sections to be more
than 80 per cent, was performed using proteinase K
treatment and phenol–chloroform extraction as pre-
viously described,9 with some modifications. Prior to
proteinase K digestion, tumour tissue was pre-incubated
in 3  sodium acetate buffer, pH 5·6, saturated with
hyaluronidase for 2 h at 37C. The pH was then adjusted
by adding 1/8 volume of 2  sodium hydroxide. Normal
DNA from a freshly collected blood sample of the same
patient was isolated using a salting-out procedure.10
Loss-of-heterozygosity analysis
Analysis of microsatellite markers was performed by
polymerase chain reaction (PCR) on 100 ng of DNA as
described by Weber and May11 using 1 Ci of
[32P]dCTP in a total volume of 12 l. Thermal cycling
was performed in a programmable heatblock (MJ
Research, Watertown, MA, U.S.A.) consisting of 27
cycles with an annealing temperature of 55C. The
microsatellite markers used were selected because they
map to chromosome regions reported to be involved in
chondrosarcoma. Apart from primers in the EXT and
EXT-like region, primers were chosen in the p5312 and
Rb12 region, at 9p21,13 and at 10p15 and 10q11.14
Polymorphic markers are described in the Genome
Database (http://gdbwww.gdb.org). Chromosomes 4,
13, and 17 were investigated in detail using D4S230,
D4S43, D4S189, D4S190, D4S1629, D4S231, D4S192,
D4S175, D4S171, D4S194, ANT1, D13S175, D13S115,
D13S217, FLT1, D13S220, D13S168, D13S124,
D13S159, D13S173, D17S1532, D17S578, D17S520,
D17S514, THRA1, D17S855, D17S1322, D17S1323,
D17S1327, D17S579, D17S588, HOX2B, MPO, HGF,
D17S1818, D17S1861, and D17S1692. After electro-
phoresis on a 6·5 per cent polyacrylamide gel containing
7  urea, gels were dried and exposed to X-ray films.
Signal intensities were measured by Phosphor Imaging
(Molecular Dynamics, Sunyvale, CA, U.S.A.). LOH
was scored when the quotient of the ratios of both alleles
of normal and tumour was larger than or equal to
1·7.15 Ratios between 1·3 and 1·7 were regarded as
inconclusive.16
Comparative genomic hybridization
The CGH procedure was based on the protocol
described by Kallioniemi et al.,17 with a few modifica-
tions as described previously.18 Briefly, test DNA was
directly labelled with FITC-dUTP and reference DNA
was labelled with lissamine-dUTP (NEN LifeSciences,
duPont), both by nick translation. Nick-translated frag-
ment sizes ranged from 400 to 2000 bp. Two hundred
nanograms of each labelled DNA and 10 g of Cot-1ig. 1—Histological appearance of the primary resection specimen.
bove, the moderately cellular cartilaginous component can be seen.
he boundary between the two components is remarkably sharp. The
naplastic component showed a high-grade spindle cell tumour in
hich transformation to an osteosarcomatous phenotype was seenJ. Pathol. 189: 454–462 (1999)
456 J. V. M. G. BOVEuE ET AL.DNA were hybridized to normal male metaphases and
incubated at 37C for 4 days. Post-hybridization washes
were performed with 2SSC at 37C, followed by
0·1SSC at 60C. Slides were counterstained with
DAPI in an antifade solution. Digital images were
analysed using QUIPS XL software from Vysis
(Downers Grove, IL, U.S.A.). Losses of DNA sequences
were defined as chromosomal regions where the average
green-to-red ratio and its 95 per cent confidence interval
are below 0·9, and gains above 1·1. These threshold
values were based on measurements from a series of
normal controls.
DNA flow cytometry
Single cell suspensions from fresh frozen tissue for
single-parameter nuclear DNA flow cytometry (FCM)
were prepared by the method of Vindelov et al.19 and
measured on a FACSCalibur flow cytometer (Becton
Dickinson, Mountain View, CA, U.S.A.). Trout red
blood cells served as an internal standard for determi-Copyright  1999 John Wiley & Sons, Ltd.nation of the G1 cell DNA content.20 ModFitLT
V2.0 software was used for data acquisition. DNA
histograms were evaluated according to accepted
criteria.21
Immunohistochemistry
Monoclonal antibodies directed to Ki-67, clone MIB1
(Immunotech SA, Marseilles, France) and p53, clone
DO-7 (DAKO, Glostrup, Denmark) were used. Immu-
nohistochemical reactions were performed on formalin-
fixed, paraffin-embedded tumour sections according to
standard laboratory methods.22 As a negative control,
slides were incubated with phosphate-buffered saline
containing 1 per cent bovine serum albumin, instead of
primary antibodies. Positive controls included a normal
tonsil for Ki-67 and a p53-positive colorectal carcinoma
for p53. Ki-67-positive nuclei were counted per 200
tumour cells, in areas containing the largest number of
positive cells.Table I—List of the microsatellite markers tested. Mean allelic imbalance ratios are given for both the
cartilaginous and the anaplastic components. Ratios above 1·7 were considered as loss of heterozygosity










EXT1 D8S85 8q23.3 0·74 1 1
D8S547 8q24.11 0·66 n.i. n.i.
D8S522 8q24.12–13 0·71 n.i. n.i.
D8S198 8q24.13 0·83 1 1
EXT2 D11S905 11p13-p12 0·74 1·12 1·54
D11S903 11p13-q13 0·74 1 1
D11S554 11p11.2–12 0·91 1 1·77
EXT3 D19S216 19pter-qter 0·75 1·11 1·08
D19S413 19pter-qter 0·76 n.i. n.i.
D19S221 19p13.2 0·86 1 1
EXTL1 D1S436 1p36 0·75 1·14 1·33
D1S470 1p36 0·76 1·04 1·48
EXTL2 D1S206 1p11–12 0·82 1·06 1·28
D1S248 1p11–12 0·82 n.i. n.i.
EXTL3 D8S1130 8p12-p22 0·93 1·12 3·3
gata119c 8p12-p21 n.i. n.i.
D8S1820 8p 0·73 1·08 3·27
D8S283 8p 0·78 1·05 2·92
p53 TP 53 17p13.1 0·69 4·69 2·91
D17S513 17p13.3 0·89 7·6 4·8
Rb D13S153 13q14.1–14.3 0·82 4·8 3·96
D13S155 13q14.3-q21.2 0·83 3·55 2·02
10p15 D10S559 10pter-p11.2 0·80 n.i. n.i.
D10S1435 10p 0·32 1·01 3·3
D10S89 10p n.i. n.i.
10q11 D10S604 10pter-qter 0·66 n.i. n.i.
D10S538 10pter-qter 0·73 1·01 2·03
D10S109 10q11.2-qter 0·71 1·16 2·4
D10S110 10q11.2-qter 0·58 n.i. n.i.
D10S185 10q23-24 0·77 1·05 2·01
D10S575 10q26 0·63 1·1 2.1
9p21 D9S43 9p21 0·83 1·1
D9S171 9p21 0·80 1·03 1·27
n.i.= non-informative (homozygous) at the locus; =upper allele lost; =lower allele lost.J. Pathol. 189: 454–462 (1999)
457HISTOGENESIS OF DEDIFFERENTIATED CHONDROSARCOMAp53 mutation analysis
PCR for exons 5–8 of the p53 gene was performed on
100 ng of DNA in a total volume of 25 l containing
12·5 pmol of the forward and 12·5 pmol of the reverse
primer, 1 per cent BSA, 0·01 per cent gelatin, 0·1 per
cent Triton X-100, 10 m Tris–HCl (pH 9·0), 50 m
KCl, 1·5 m MgCl2, 0·2 m dNTP, and 0·06 U ofCopyright  1999 John Wiley & Sons, Ltd.SuperTaq DNA polymerase (Sphaero Q, HT Biotech-
nology Ltd., Cambridge, U.K.). The primers used for
amplification were: exon 5 forward: TTCCTCTTCCT
GCAGTACTC, reverse: TCTCTGCTGTCCCGACC
AAC; exon 6 forward: TGGGGCTGGAGAGACGAC,
reverse: AGGGATATTGGGGTACTCTACAC; exon
7 forward: GTGTTATCTCCTAGGTTGGC, reverse:
AGGTCCAGTCCTCGGTGAAC; exon 8 forward:
TGATTTCCTTACTGCCTCTTG, reverse: CACGT-
CAATACGGAGTCTAA. Thermal cycling was per-
formed in a programmable heatblock (Perkin Elmer
Cetus, Norwalk, CT, U.S.A.) using a ‘touchdown’ PCR
program of 47 cycles consisting of two cycles with
annealing at 65C, two cycles at 64C, two cycles at
63C, two cycles at 62C, two cycles at 61C, two cycles
at 60C, four cycles at 59C, six cycles at 58C, and 25
cycles at 57C. PCR products were purified using Micro-
Spin G-50 columns (Pharmacia Biotech, Uppsala,
Sweden). Subsequent sequencing reactions were per-
formed using the ABI Prism BigDye Terminator Cycle
Sequencing Ready Reaction Kit, according to the manu-
facturer’s recommendations (Perkin Elmer Applied Bio-
systems, Foster City, CA, U.S.A.). Samples were run on
the ABI 377 semi-automated sequencer (Perkin Elmer,
The Netherlands). Both strands were sequenced.
RESULTS
Loss of heterozygosity (LOH)
The cartilaginous component demonstrated LOH at
17p13, 13q14, and chromosome 4 (Tables I and II). The
anaplastic component demonstrated loss of the same
alleles on 17p13 and 13q14 and, additionally, LOH was
detected on chromosomes 8, 10, and 11. LOH at chro-
mosome 4 was also identified, but involved the other
allele than in the cartilaginous component (Table II).
This phenomenon involved all markers tested, spanning
chromosome 4. For all markers spanning chromosome
13, the same allele was lost in both components. OnFig. 2—Examples of autoradiograms. Microsatellite markers are indicated above each
panel. N=normal DNA; C=cartilaginous component; A=anaplastic component.
Allelic imbalance ratios are given in Tables I and IITable 2—Loss of heterozygosity analysis on chromosomes 4,
13, and 17 was performed using markers spanning the whole
chromosome. Only heterozygous markers are shown. Allelic









D4S174 4p21.1-p14 6·34 2·80
D4S230 4pter-p15 6·63 3·64
D4S43 4p16.3 6·27 2·94
D4S190 4p21.1-p14 2·19 1·77
D4S1629 4pter-qter 6·34 3·19
D4S192 4q25-34 5·82 3·50
D4S175 4q31 7·12 2·72
ANT1 4q35 3·63 2·90
D13S115 13q11–12.1 3·75 2·70
FLT1 13q12 5·47 3·37
D13S153 13q14.1-q14.3 4·8 3·96
D13S155 13q14.3-q21.2 2 2
D13S168 13q14.3 7·03 4·75
D13S159 13q32 6·99 2·98
D17S513 17p13.3 7·6 4·8
TP 53 17p13.1 4·69 2·91
D17S520 17p12 8·66 3·88
THRA1 17q11.1-q12 15·67 8·17
D17S855 17q21 1·77 4·19
D17S588 17q 1·69 3·57
=upper allele lost; =lower allele lost.
*Ratios above 1·7 were considered as LOH and are in bold.
Inconclusive ratios are given in italics.J. Pathol. 189: 454–462 (1999)
458 J. V. M. G. BOVEuE ET AL.chromosome 17, both components showed loss of the
same allele for markers located on the short arm and the
centromeric part of the long arm, whereas on the rest of
the long arm, different alleles were lost in the two
components, with relatively low allelic imbalance ratios
in the cartilaginous component (Table II). Examples are
shown in Fig. 2.
Comparative genomic hybridization
The cartilaginous component was characterized by the
deletion of chromosomes 4, 5, 13, 22 and the distal partCopyright  1999 John Wiley & Sons, Ltd.of chromosome 16p. Chromosome 17 revealed a
deletion: del(17)(pter-q12) and an amplification on the
long arm. In contrast, the anaplastic component demon-
strated amplification on 2p, 8q, 10q, 11q, 12p, 12q, 19p,
and possibly on 1p. Deletion was seen on 2q, 4, 5q, 13,
Xp, and Xq (Fig. 3).
Flow cytometry
Flow cytometric analysis demonstrated two peri-
diploid clones in the cartilaginous component, with
DNA indices of 0·95 and 1·11. The anaplastic compo-
nent revealed two highly aneuploid clones of 1·60 and
2·84 respectively (Fig. 4).
Immunohistochemistry
p53 immunoreactivity was seen in both components
present in the primary tumour (Figs 5A and 5B), as well
as in the anaplastic component of the recurrence. Pro-
liferative activity in the primary tumour was higher in
the anaplastic component than in the cartilaginous
component (45 per cent versus 16 per cent Ki-67-positive
cells), whereas in the recurrence specimen, 75 per cent
positive cells were found.
p53 mutation analysis
Mutation analysis revealed a 6 bp deletion
(CCATCC) starting at the second base of codon 250 in
exon 7 in both the cartilaginous and the anaplastic
component which was absent in normal DNA of the
patient (Figs 5C and 5D). The deletion leads to the
elimination of the amino acids proline and isoleucine
from the central DNA-binding domain of the p53
protein.
DISCUSSION
In 1971, Dahlin and Beabout first described dediffer-
entiated chondrosarcoma as a rare variant within theFig. 3—Examples of unbalances found by CGH analyses in the
cartilaginous and anaplastic components. The profiles show the aver-
age fluorescence intensity ratios and its 95 per cent confidence interval.
Over- and under-representations are shown as grey bars on the right
and black bars on the left sides of the ideograms, respectively.Fig. 4—Flow cytometric DNA histograms from nuclear suspensions of both the cartilaginous
and the anaplastic component. Both demonstrate two different tumour cell clones, the
cartilaginous component with peri-diploid DNA indices and the anaplastic component with
highly aneuploid DNA indices.J. Pathol. 189: 454–462 (1999)
459HISTOGENESIS OF DEDIFFERENTIATED CHONDROSARCOMAspectrum of malignant cartilaginous tumours. They
explained the co-existence of the cartilaginous and ana-
plastic components as dedifferentiation of a well-
differentiated cartilaginous tumour cell to a primitive
undifferentiated tumour cell23 (Fig. 6A). Sanerkin
and Woods explained the presence of the anaplastic
component as an independently developing sarcoma,
arising within the reactive fibrous tissue surrounding
necrotic areas in a pre-existing benign cartilaginous
lesion.7 Since both components would then arise within
different tissues, dedifferentiated chondrosarcoma
should be referred to as a ‘collision’ tumour (Fig. 6B).
Currently, the generally supported hypothesis is that
high-grade elements represent a failure of differentia-
tion, rather than dedifferentiation of mature chondroid
cells.6,24 It is still debated as to whether the two
components are derived from two separate clones of
cells (collision tumour)5,6 (Fig. 6B), or whether
both components arise from a common primitive
mesenchymal cell progenitor, possessing both the ability
to differentiate and express chondrocytic features andCopyright  1999 John Wiley & Sons, Ltd.the ability to express features of high-grade sarcomas4
(Fig. 6C).
Phenotypic characteristics of both components have
been studied intensively by electron microscopy and
immunohistochemistry. Most ultrastructural studies
revealed the lack of chondroid features in the anaplastic
component.6,25,26 Sparse S-100 protein-positive cells in
the anaplastic component were interpreted as reflecting a
retained potential for primitive chondrogenesis.26,27 An
immunohistochemical study for collagen subtypes and
cartilage proteoglycans indicated a non-chondrocytic
nature of the anaplastic component, favouring the ‘col-
lision tumour’ theory.28 Since these studies are based on
phenotypically reversible features, they do not provide
evidence for the histogenesis of dedifferentiated
chondrosarcoma, in contrast to studies investigating
irreversible, fixed molecular genetic alterations.
Comparative molecular genetic studies of both com-
ponents of dedifferentiated chondrosarcoma are sparse.
Cytogenetic analysis was performed in eight cases4,29–33
and characteristic alterations have not been demon-Fig. 5—p53 immunoreactivity was detected in both the cartilaginous (A) and the anaplastic (B) component. Sequencing results of exon 7 revealed
a 6 bp deletion which was found in both components and not in DNA derived from peripheral blood (C). Starting at nucleotide 749, the second base
of codon 250, two sequences running through each other can be detected and are indicated below. The upper sequence is the wild type, whereas the
lower is the mutated sequence. PCR products of exon 7 were run on an agarose gel containing 3 per cent NuSieve GTG combined with 1 per cent
Seakem GTG (both purchased from FMC BioProducts, Rockland, Maine, U.S.A.) (D). The 6 bp deletion was confirmed in both the cartilaginous
and the anaplastic component and was not present in the germlineJ. Pathol. 189: 454–462 (1999)
460 J. V. M. G. BOVEuE ET AL.strated. Most karyotypes are probably derived from the
anaplastic component, overgrowing the slowly dividing
cartilaginous component in tissue culture. Bridge et al.
were the first to combine cytogenetic analysis with
immunophenotyping and showed numerical aberrations
of chromosome 7 in both components of dedifferen-
tiated chondrosarcoma,4 which would suggest that both
were derived from a single abnormal clone or cell.
However, it cannot be completely ruled out that both
components independently obtained an extra chromo-
some 7. Extra copies of chromosome 7 were seen in
three other cases,30,32,33 while CGH analysis of the
present case did not show copy number changes of
chromosome 7.
The results of the present case provide strong evidence
to support a common origin. In both components, we
identified an identical 6 bp deletion in p53 which was
not reported in a p53 mutation database (http://Copyright  1999 John Wiley & Sons, Ltd.p53.genome.ad.jp) and is therefore not regarded as a
mutational hotspot. This provides strong evidence for a
monoclonal origin and excludes a collision tumour in
this case of dedifferentiated chondrosarcoma (Fig. 6D).
Furthermore, LOH at 17p and 13 involved the same
alleles.
However, we also found clear genetic differences. The
anaplastic component showed LOH at additional loci
that were not involved in the cartilaginous component
(11p11.2–12, 8p, and chromosome 10), and amplifi-
cation and deletion of several chromosome parts as
demonstrated by CGH. In contrast, the cartilaginous
component had lost chromosomes 5, 22, and the tip of
16p and revealed an amplification on 17q. Although at
17p both components lost the same alleles for all micro-
satellite markers tested, CGH analysis revealed a
deletion of 17p in the cartilaginous component only.
LOH analysis further revealed that both componentsFig. 6—Theories of the histogenesis of dedifferentiated chondrosarcoma. (A) Originally it was thought that a well-differentiated
cartilaginous tumour cell dedifferentiates into a primitive undifferentiated tumour cell.23 (B) The two components are derived from two
separate clones of cells (collision tumour), one of which differentiates into a low-grade chondrosarcoma, while the other fails to
differentiate and displays features of high-grade sarcoma.5,6,28 (C) Both components of dedifferentiated chondrosarcoma display
numerical aberrations of chromosome 7,4 suggesting that both components are derived from a single abnormal clone or cell. (D) The
present case provides compelling evidence for a monoclonal origin, since both components have specific genetic alterations in common.
However, the presence of many additional different genetic alterations suggests that the separation of the two clones was a relatively early
eventJ. Pathol. 189: 454–462 (1999)
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the DNA indices indicate that it is unlikely that simple
polyploidization of the 0·95 and 1·11 clone of the
cartilaginous component has occurred in the anaplastic
component, with DNA indices 1·60 and 2·84. Thus, our
data show that many genetic alterations have occurred
after the diversion of the two components and therefore
suggest that the separation of the two clones was a
relatively early event in the histogenesis of this dediffer-
entiated chondrosarcoma (Fig. 6D). This early separ-
ation may explain why many studies on the
phenotypically reversible features of the two compo-
nents demonstrated very different phenotypes, leading to
the conclusion that dedifferentiated chondrosarcoma is a
collision tumour.6,7,25,26,28 It remains unclear, however,
whether (primitive) chondroid features are expressed
before the divergence of the two components, support-
ing the original idea of ‘dedifferentiation’, or after the
separation of the two lines of differentiation.
Since fresh-frozen tumour tissue of the anaplastic
component was derived from the tumour recurrence
specimen, we cannot completely rule out the possibility
that some of the alterations detected in the anaplastic
component are additional aberrations of the recurrence
that occurred in the course of tumour progression.
Unfortunately, DNA extracted from formalin-fixed,
paraffin-embedded decalcified bone tumour tissue most
often fails in PCR amplification and comparative
genomic hybridization.
The p53 alteration being an early event in chondro-
sarcomas is in contrast with the literature, since p53
overexpression and mutation are mainly found in
high-grade chondrosarcomas.12,34,35 Previously, p53
overexpression was reported in four dedifferentiated
chondrosarcomas in the anaplastic component,34
whereas only focal weak positivity was noted in the
cartilaginous areas. In another case, no immuno-
reactivity was seen in the cartilaginous component and
in a fibrosarcomatous component, while a MFH-like
portion demonstrated strong immunoreactivity. A mis-
sense mutation (ArgThr in codon 249 of exon 7) was
only found in DNA from the p53-positive area and was
absent in the p53-negative specimens,36 suggesting that
in this case, p53 was involved after the divergence of the
two components. The presence of p53 overexpression
and mutation in both components of the present case
may be explained by the fact that the cartilaginous
component was grade II according to Evans,8 while
most dedifferentiated chondrosarcomas reported display
a grade I cartilaginous component, as originally
defined.23 Capanna et al. showed, however, that the
cartilaginous component was of moderate to high histo-
logical grade in 25 of 46 (54 per cent) dedifferentiated
chondrosarcomas.3
In conclusion, the molecular genetic characterization
of this case of dedifferentiated chondrosarcoma provides
strong evidence for a monoclonal origin, since both
components share an identical p53 mutation and
deletion of the same copies of chromosome 13. Many
different genetic alterations were also demonstrated,
which occurred after the diversion of the two compo-
nents. These results suggest that the separation of theCopyright  1999 John Wiley & Sons, Ltd.two clones may be an early event in the histogenesis of
dedifferentiated chondrosarcoma.
ACKNOWLEDGEMENTS
We would like to thank N. J. Kuipers-Dijkshoorn,
L. J. C. M. van den Broek, E. Geelen, and A. M.
Kersenmaekers for expert technical assistance and Dr F.
Graadt van Roggen for critically reading the manu-
script. This study was financially supported by the Sacha
Swarttouw-Hijmans Foundation and the Post Graduate
School for Molecular Medicine.
REFERENCES
1. Dorfman HD, Czerniak B (eds). Bone Tumors. Mosby: St Louis, 1998.
2. Huvos AG (ed.). Bone Tumors. Diagnosis, Treatment, and Prognosis (2nd
edn). W. B. Saunders: Philadelphia, 1991.
3. Capanna R, Bertoni F, Bettelli G, et al. Dedifferentiated chondrosarcoma.
J Bone Joint Surg [Am] 1988; 70A: 60–69.
4. Bridge JA, DeBoer J, Travis J, et al. Simultaneous interphase cytogenetic
analysis and fluorescence immunophenotyping of dedifferentiated chondro-
sarcoma; implications for histopathogenesis. Am J Pathol 1994; 144: 215–
220.
5. Rywlin AM, Robb JA. Chondrosarcoma of bone with ‘dedifferentiation’.
Hum Pathol 1982; 13: 963–964.
6. Tetu B, Ordonez NG, Ayala AG, Mackay B. Chondrosarcoma with
additional mesenchymal component (dedifferentiated chondrosarcoma) II.
An immunohistochemical and electron microscopic study. Cancer 1986; 58:
287–298.
7. Sanerkin NG, Woods CG. Fibrosarcomata and malignant fibrous histio-
cytomata arising in relation to enchondromata. J Bone Joint Surg [Br]
1979; 61B: 366–372.
8. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondro-
sarcoma of bone. A clinicopathologic analysis with emphasis on histologic
grading. Cancer 1977; 40: 818–831.
9. Devilee P, Van den Broek M, Kuipers-Dijkshoorn N, et al. At least four
different chromosomal regions are involved in loss of heterozygosity in
human breast carcinoma. Genomics 1989; 5: 554–560.
10. Miller SA, Polesky HF. A simple salting out procedure for extracting DNA
from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
11. Weber JL, May PE. Abundant class of human DNA polymorphisms which
can be typed using the polymerase chain reaction. Am J Hum Genet 1989;
44: 388–396.
12. Yamaguchi T, Toguchida J, Wadayama B, et al. Loss of heterozygosity and
tumor suppressor gene mutations in chondrosarcomas. Anticancer Res 1996;
16: 2009–2016.
13. Jagasia AA, Block JA, Qureshi A, et al. Chromosome 9 related aberrations
and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in
human chondrosarcomas. Cancer Lett 1996; 105: 91–103.
14. Raskind WH, Conrad EU, Matsushita M. Frequent loss of heterozygosity
for markers on chromosome arm 10q in chondrosarcomas. Genes Chromo-
somes Cancer 1996; 16: 138–143.
15. Gruis NA, Abeln ECA, Bardoel AFJ, Devilee P, Frants RR, Cornelisse CJ.
PCR-based microsatellite polymorphisms in the detection of loss of hetero-
zygosity in fresh and archival tumour tissue. Br J Cancer 1993; 68: 308–313.
16. Devilee P, Van Vliet M, Bardoel AFJ, et al. Frequent somatic imbalance of
marker alleles for chromosome 1 in human primary breast carcinoma.
Cancer Res 1991; 51: 1020–1025.
17. Kallioniemi O, Kallioniemi A, Piper J, et al. Optimizing comparative
genomic hybridization for analysis of DNA sequence copy number changes
in solid tumors. Genes Chromosomes Cancer 1994; 10: 231–243.
18. Rosenberg C, Van Gijlswijk RPM, Vos CBJ, et al. Comparative
genomic hybridization with lissamine- and fluorescein labelled nucleotides.
Cytometry 1998; 32: 337–341.
19. Vindelov LL, Christensen IJ, Nissen NI. A detergent–trypsin method for the
preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3:
323–327.
20. Vindelov LL, Christensen IJ, Nissen NI. Standardization of high-resolution
flow cytometric DNA analysis by the simultaneous use of chicken and trout
red blood cells as internal reference standards. Cytometry 1983; 3: 328–331.
21. Hiddemann W, Schumann J, Andreef M, et al. Convention on nomen-
clature for DNA cytometry. Committee on Nomenclature, Society for
Analytical Cytology. Cancer Genet Cytogenet 1984; 13: 181–183.
22. Bovee JVMG, Van den Broek LJCM, De Boer WI, Hogendoorn PCW.
Expression of growth factors and their receptors in adamantinoma of long
bones and the implications for its histogenesis. J Pathol 1998; 184: 24–30.J. Pathol. 189: 454–462 (1999)
462 J. V. M. G. BOVEuE ET AL.23. Dahlin DC, Beabout JW. Dedifferentiation of low-grade chondrosarcomas.
Cancer 1971; 28: 461–466.
24. Johnson S, Tetu B, Ayala AG, Chawla SP. Chondrosarcoma with
additional mesenchymal component (dedifferentiated chondrosarcoma). I.
A clinicopathologic study of 26 cases. Cancer 1986; 58: 278–286.
25. Kahn LB. Chondrosarcoma with dedifferentiated foci; a comparative and
ultrastructural study. Cancer 1976; 37: 1365–1375.
26. Abenoza P, Neumann MP, Manivel JC, Wick MR. Dedifferentiated
chondrosarcoma: an ultrastructural study of two cases, with immunocyto-
chemical correlations. Ultrastruct Pathol 1986; 10: 529–538.
27. Wick MR, Siegal GP, Mills SE, Thompson RC, Sawhney D, Fechner RE.
Dedifferentiated chondrosarcoma of bone; an immunohistochemical and
lectin-histochemical study. Virchows Arch [A] 1987; 411: 23–32.
28. Aigner T, Dertinger S, Neureiter D, Kirchner T. De-differentiated chondro-
sarcoma is not a ‘de-differentiated’ chondrosarcoma. Histopathology 1998;
33: 11–19.
29. Zalupski MM, Ensley JF, Ryan J, Selvaggi S, Baker LH, Wolman SR. A
common cytogenetic abnormality and DNA content alterations in dediffer-
entiated chondrosarcoma. Cancer 1990; 66: 1176–1182.Copyright  1999 John Wiley & Sons, Ltd.30. Ozisik YY, Meloni AM, Peier A, et al. Cytogenetic findings in 19 malignant
bone tumors. Cancer 1994; 74: 2268–2275.
31. Tarkkanen M, Wiklund T, Virolainen M, Elomaa I, Knuutila S. Dediffer-
entiated chondrosarcoma with t(9;22)(q34;q11–12). Genes Chromosomes
Cancer 1994; 9: 136–140.
32. Swarts SJ, Neff JR, Johansson SL, Bridge JA. Cytogenetic analysis of
dedifferentiated chondrosarcoma. Cancer Genet Cytogenet 1996; 89: 49–51.
33. Sawyer JR, Swanson CM, Lukacs JL, Nicholas RW, North PE, Thomas
JR. Evidence of an association between 6q13–21 chromosome aberrations
and locally aggressive behavior in patients with cartilage tumors. Cancer
1998; 82: 474–483.
34. Coughlan B, Feliz A, Ishida T, Czerniak B, Dorfman HD. p53 expression
and DNA ploidy of cartilage lesions. Hum Pathol 1995; 26: 620–624.
35. Dobashi Y, Sugimura H, Sato A, et al. Possible association of p53
overexpression and mutation with high-grade chondrosarcoma. Diagn Mol
Pathol 1993; 2: 257–263.
36. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y,
Yamamuro T. p53 expression and its relationship to DNA alterations in
bone and soft tissue sarcomas. Br J Cancer 1993; 68: 1134–1139.J. Pathol. 189: 454–462 (1999)
